ATTR Cardiac Amyloidosis in a Selected Population

Helse Møre og Romsdal HF

Status: Enrolling

Conditions: Cardiac Amyloidosis; ATTR Amyloidosis Wild Type; Carpal Tunnel Syndrome; ATTR Gene Mutation

Study type: Observational

Funder types: Other

Identifiers

NCT06458374

715238

Details and patient eligibility

About

Patients operated for carpal tunnel syndrome (CTS) at Ålesund Hospital (200 patients) will have a biopsy to diagnose ATTR amyloidosis. Patients with positive biopsy will be examined to decide wether they have cardiac amyloidosis. All patients with positive biopsy will be followed closely for 10 years wit echocardiography an clinically.

Full description

Biopsy proven ATTR (v/wt) amyloidosis inpatients operated with CTS will undergo standard guidelines recommended examinations as 99mTcDPD SPECT CT, echocardiography, ECG, Holter, genetic testing (v/wt), and lab testing, and CMRI as indicated. Exclusion of light chain disease will be done.

All patients will be followed at least yearly as indicated by guidelines (ESC), and patients with development of cardiac amyloidosis will get standard treatment in accordance with guidelines and as approved by the Norwegian government. All patients will be followed for 10 years.

Enrollment: 180 estimated patients

Sex: All

Ages: 50+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male > 50 years
• Female > 60 years
• operated CTS at Ålesund Hospital

Exclusion criteria

• not consented
• do not speak Norwegian
• secondary cause of CTS as traumatic or rheumatic
• cannot be followed > 5 years due to other medical conditions
• Cardiac disease at time of operation for CTS